{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:09:35Z","timestamp":1781788175962,"version":"3.54.5"},"reference-count":34,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,5]]},"abstract":"\n Aim:<\/jats:bold>\n To indirectly compare the efficacy and safety of elafibranor and seladelpar, as second-line treatments for primary biliary cholangitis.\n Materials & methods:<\/jats:bold>\n Bayesian network meta-analyses compared data from randomized-controlled studies of elafibranor and seladelpar identified by a systematic literature review up to June 2024: (a) elafibranor (n\u00a0=\u00a0108) versus placebo (n\u00a0=\u00a053; ELATIVE [\n NCT04526665<\/jats:ext-link>\n ]) and (b) seladelpar (n\u00a0=\u00a0128) versus placebo (n\u00a0=\u00a065; RESPONSE [\n NCT03301506<\/jats:ext-link>\n ]). Patients from ELATIVE not meeting the RESPONSE upper limit of normal (ULN) criteria for alkaline phosphatase (ALP) and total bilirubin were excluded (n\u00a0=\u00a016); summary statistics for ELATIVE were recalculated using the new dataset. Random-effects models assessed the outcomes of cholestasis response (ALP\u00a0<1.67\u00a0\u00d7\u00a0ULN, ALP reduction \u226515% from baseline and total bilirubin \u2264ULN), ALP normalization, change from baseline in ALP and pruritus, pruritus as a treatment-emergent adverse event and all-cause discontinuation.\n Results:<\/jats:bold>\n Elafibranor-treated patients had greater odds of achieving cholestasis response than placebo- (median odds ratio [95% credible interval]: 84.79 [12.49, 2513.00]) or seladelpar-treated patients (13.02 [1.45, 420.20]), with posterior probabilities \u226599% that odds were higher with elafibranor than seladelpar or placebo. Among patients with ALP \u2265350\u00a0U\/l, the median odds ratio [95% credible interval] of cholestasis response for elafibranor-treated patients versus seladelpar-treated patients was 18.71 [0.65, 10,610.00], with a 95.2% posterior probability that odds were higher with elafibranor than seladelpar. For all other outcomes, there was no strong evidence of a difference between treatments.\n Conclusion:<\/jats:bold>\n Bayesian network meta-analyses found strong probabilistic evidence supporting the treatment benefit of elafibranor compared with seladelpar for the achievement of cholestasis response at 52\u00a0weeks, while the treatment effect on other outcomes was uncertain. Head-to-head studies are needed to validate results of these indirect comparisons.\n <\/jats:p>","DOI":"10.57264\/cer-2025-0206","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:38:00Z","timestamp":1776433080000},"source":"Crossref","is-referenced-by-count":1,"title":["Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0083-5564","authenticated-orcid":false,"given":"David","family":"Jones","sequence":"first","affiliation":[{"name":"Institute of Cellular Medicine & NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Combe","sequence":"additional","affiliation":[{"name":"FIECON, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun","family":"Knight","sequence":"additional","affiliation":[{"name":"FIECON, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-6391","authenticated-orcid":false,"given":"Vicki","family":"Laskier-Owens","sequence":"additional","affiliation":[{"name":"FIECON, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-7124","authenticated-orcid":false,"given":"Shijie","family":"Ren","sequence":"additional","affiliation":[{"name":"Sheffield Centre for Health & Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Wright","sequence":"additional","affiliation":[{"name":"FIECON, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A","family":"B\u00f6ing","sequence":"additional","affiliation":[{"name":"Ipsen, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6210-3781","authenticated-orcid":false,"given":"Alex","family":"Pashley","sequence":"additional","affiliation":[{"name":"Costello Medical, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"5","key":"e_1_3_10_3_2","doi-asserted-by":"crossref","first-page":"e0197117","DOI":"10.1371\/journal.pone.0197117","article-title":"Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications","volume":"13","author":"Axley P","year":"2018","unstructured":"Axley P, Mudumbi S, Sarker S, Kuo Y-F, Singal A. Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications. PLoS ONE 13(5), e0197117 (2018).","journal-title":"PLoS ONE"},{"issue":"2","key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi PJ","year":"2016","unstructured":"Trivedi PJ, Lammers WJ, van Buuren HR Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 65(2), 321\u2013329 (2016).","journal-title":"Gut"},{"issue":"9","key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2468-1253(25)00025-1","article-title":"Primary biliary cholangitis and the narrowing gap towards optimal disease control","volume":"10","author":"Can\u00e7ado GGL","year":"2025","unstructured":"Can\u00e7ado GGL, Lleo A, Levy C, Trauner M, Hirschfield GM. Primary biliary cholangitis and the narrowing gap towards optimal disease control. Lancet Gastroenterol. Hepatol. 10(9), 855\u2013870 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor KD","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore) 69(1), 394\u2013419 (2019).","journal-title":"Hepatology (Baltimore)"},{"issue":"1","key":"e_1_3_10_7_2","first-page":"49","article-title":"Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches","volume":"8","author":"Galoosian A","year":"2020","unstructured":"Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches. J. Clin. Transl. Hepatol. 8(1), 49\u201360 (2020).","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"4","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3350\/cmh.2012.18.4.375","article-title":"Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score","volume":"18","author":"Jung HE","year":"2012","unstructured":"Jung HE, Jang JY, Jeong SW Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score. Clin. Mol. Hepatol. 18(4), 375\u2013382 (2012).","journal-title":"Clin. Mol. Hepatol."},{"issue":"6","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000506980","article-title":"Quality of life in patients with primary biliary cholangitis: a single-center experience in Serbia","volume":"38","author":"Milovanovic T","year":"2020","unstructured":"Milovanovic T, Popovic D, Stojkovic Lalosevic M, Dumic I, Dragasevic S, Milosavljevi\u0107 T. Quality of life in patients with primary biliary cholangitis: a single-center experience in Serbia. Dig. Dis. 38(6), 515\u2013521 (2020).","journal-title":"Dig. Dis."},{"issue":"9","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield GM","year":"2018","unstructured":"Hirschfield GM, Dyson JK, Alexander GJM The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 67(9), 1568\u20131594 (2018).","journal-title":"Gut"},{"issue":"2","key":"e_1_3_10_11_2","first-page":"66","article-title":"Primary biliary cirrhosis and liver transplantation","volume":"1","author":"Akamatsu N","year":"2012","unstructured":"Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable Rare Dis. Res. 1(2), 66 (2012).","journal-title":"Intractable Rare Dis. Res."},{"issue":"6","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers WJ","year":"2014","unstructured":"Lammers WJ, van Buuren HR, Hirschfield GM Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 147(6), 1338\u20131349.e5 (2014).","journal-title":"Gastroenterology"},{"issue":"5","key":"e_1_3_10_13_2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis","volume":"32","author":"Momah N","year":"2012","unstructured":"Momah N, Silveira MG, Jorgensen R, Sinakos E, Lindor KD. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 32(5), 790\u2013795 (2012).","journal-title":"Liver Int."},{"issue":"7","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens F","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375(7), 631\u2013643 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_10_15_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley KV","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C Efficacy and safety of elafibranor in primary biliary cholangitis. N. Engl. J. Med. 390(9), 795\u2013805 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase III trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield GM","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ A Phase III trial of seladelpar in primary biliary cholangitis. N. Engl. J. Med. 390(9), 783\u2013794 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.dld.2017.05.001","article-title":"Primary biliary cholangitis: advances in management and treatment of the disease","volume":"49","author":"Invernizzi P","year":"2017","unstructured":"Invernizzi P, Floreani A, Carbone M Primary biliary cholangitis: advances in management and treatment of the disease. Dig. Liver Dis. 49(8), 841\u2013846 (2017).","journal-title":"Dig. Liver Dis."},{"issue":"4","key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5152\/tjg.2025.24300","article-title":"Clinical and biochemical characteristics of a Danish and Turkish cohort of incident and prevalent patients with primary biliary cholangitis","volume":"36","author":"Eruzun H","year":"2025","unstructured":"Eruzun H, Bossen L, G\u00f6k\u00e7e DT Clinical and biochemical characteristics of a Danish and Turkish cohort of incident and prevalent patients with primary biliary cholangitis. Turkish J. Gastroenterol. 36(4), 241 (2025).","journal-title":"Turkish J. Gastroenterol."},{"key":"e_1_3_10_19_2","unstructured":"Ipsen. Ipsen's Iqirvo\u00ae receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis. (2024). https:\/\/www.ipsen.com\/press-release\/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis\/"},{"key":"e_1_3_10_20_2","unstructured":"Gilead Sciences Inc. Gilead's Livdelzi (seladelpar) granted accelerated approval for primary biliary cholangitis by U.S. FDA. (2024). https:\/\/www.gilead.com\/news\/news-details\/2024\/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-us-fda"},{"key":"e_1_3_10_21_2","unstructured":"Ipsen. U.K. MHRA grants marketing authorisation for Ipsen's Iqirvo\u00ae (elafibranor) a first-in-class peroxisome proliferator-activated receptor (PPAR) treatment for primary biliary cholangitis (PBC). (2024). https:\/\/www.ipsen.com\/uk-ireland\/press-releases\/u-k-mhra-grants-marketing-authorisation-for-ipsens-iqirvo-elafibranor-a-first-in-class-peroxisome-proliferator-activated-receptor-ppar-treatment-for-primary-biliary-cholangitis-p\/"},{"key":"e_1_3_10_22_2","unstructured":"Medicines and Healthcare products Regulatory Agency. Seladelpar approved to treat adult patients in the UK with liver illness. (2025). https:\/\/www.gov.uk\/government\/news\/seladelpar-approved-to-treat-adult-patients-in-the-uk-with-liver-illness"},{"key":"e_1_3_10_23_2","unstructured":"Gilead Sciences Inc. Gilead's seladelpar granted conditional European marketing authorization for the treatment of primary biliary cholangitis. (2025). https:\/\/www.gilead.com\/news\/news-details\/2025\/gileads-seladelpar-granted-conditional-european-marketing-authorization-for-the-treatment-of-primary-biliary-cholangitis"},{"key":"e_1_3_10_24_2","unstructured":"Ipsen. Ipsen's Iqirvo\u00ae (elafibranor) approved in the European union as first new treatment for primary biliary cholangitis in nearly a decade. (2024). https:\/\/www.ipsen.com\/press-release\/ipsens-iqirvo-elafibranor-approved-in-the-european-union-as-first-new-treatment-for-primary-biliary-cholangitis-in-nearly-a-decade-2949674\/"},{"issue":"6","key":"e_1_3_10_25_2","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg JM","year":"2021","unstructured":"Schattenberg JM, Pares A, Kowdley KV A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J. Hepatol. 74(6), 1344\u20131354 (2021).","journal-title":"J. Hepatol."},{"key":"e_1_3_10_26_2","volume-title":"Systematic reviews: CRD's guidance for undertaking reviews in health care","author":"Akers J","year":"2009","unstructured":"Akers J, Aguiar-Ib\u00e1\u00f1ez R, Baba-Akbari A. Systematic reviews: CRD's guidance for undertaking reviews in health care. Centre for Reviews and Dissemination, University of York, UK (2009)."},{"key":"e_1_3_10_27_2","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).","journal-title":"BMJ"},{"key":"e_1_3_10_28_2","volume-title":"Decision Support Unit, NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias S","year":"2014","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. Decision Support Unit, NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence, UK (2014)."},{"key":"e_1_3_10_29_2","volume-title":"OpenBUGS User Manual, Version 3.0.2","author":"Spiegelhalter D","year":"2007","unstructured":"Spiegelhalter D, Thomas A, Best N, Lunn D. OpenBUGS User Manual, Version 3.0.2. MRC Biostatistics Unit, UK (2007)."},{"key":"e_1_3_10_30_2","unstructured":"The R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing (2024)."},{"key":"e_1_3_10_31_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v012.i03","article-title":"R2WinBUGS: a package for running WinBUGS from R","volume":"12","author":"Sturtz S","year":"2005","unstructured":"Sturtz S, Ligges U, Gelman A. R2WinBUGS: a package for running WinBUGS from R. J. Stat. Softw. 12, 1\u201316 (2005).","journal-title":"J. Stat. Softw."},{"key":"e_1_3_10_32_2","first-page":"A239","article-title":"P250 beyond the mean: exploring the impact of baseline alkaline phosphatase levels on endpoints in primary biliary cholangitis","volume":"74","author":"Levy C","year":"2025","unstructured":"Levy C, Bowlus C, Lawitz E P250 beyond the mean: exploring the impact of baseline alkaline phosphatase levels on endpoints in primary biliary cholangitis. Gut 74, A239\u2013A241 (2025).","journal-title":"Gut"},{"key":"e_1_3_10_33_2","unstructured":"UK-PBC. Epidemiology of PBC. (2025). https:\/\/www.uk-pbc.com\/about\/aboutpbc\/epidemiology-of-pbc\/"},{"issue":"3","key":"e_1_3_10_34_2","first-page":"154","article-title":"Update on new drugs and those in development for the treatment of primary biliary cholangitis","volume":"14","author":"Bahar R","year":"2018","unstructured":"Bahar R, Wong KA, Liu CH, Bowlus CL. Update on new drugs and those in development for the treatment of primary biliary cholangitis. Gastroenterol. Hepatol. 14(3), 154\u2013163 (2018).","journal-title":"Gastroenterol. Hepatol."},{"issue":"1","key":"e_1_3_10_35_2","doi-asserted-by":"crossref","first-page":"e16222","DOI":"10.1111\/liv.16222","article-title":"Second-line treatment for patients with primary biliary cholangitis: a systematic review with network meta-analysis","volume":"45","author":"Giannini EG","year":"2025","unstructured":"Giannini EG, Pasta A, Calabrese F Second-line treatment for patients with primary biliary cholangitis: a systematic review with network meta-analysis. Liver Int. 45(1), e16222 (2025).","journal-title":"Liver Int."},{"issue":"1","key":"e_1_3_10_36_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13643-024-02460-0","article-title":"Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis","volume":"13","author":"Lin W","year":"2024","unstructured":"Lin W, Wang J-X, Liu Y-J. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis. Sys. Rev. 13(1), 46 (2024).","journal-title":"Sys. Rev."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:52:28Z","timestamp":1779285148000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.57264\/cer-2025-0206"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0206","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"e250206"}}